Filana Therapeutics Works to Lift FDA Clinical Hold on Simufilam TSC Epilepsy Program

An active FDA Clinical Hold on simufilam remains the defining regulatory constraint for Filana Therapeutics, Inc. as the Austin-based biotech works through preclinical data submissions and protocol redesign to advance its Tuberous Sclerosis Complex epilepsy program toward IND-enabling studies. The company's path to clinical initiation depends entirely on satisfying the agency's information requests and completing FDA's subsequent review.

Filana is preparing to submit additional preclinical data alongside protocol design modifications in response to the hold. Supporting that effort, data published in Epilepsia demonstrated that simufilam attenuated seizure progression in a well-validated mouse model of severe TSC-related epilepsy, with results showing a positive correlation between seizure outcomes and plasma exposure to the compound. The program was also presented at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices in Madrid on May 5, 2026, where the biological rationale for continued evaluation was outlined. TSC-related epilepsy affects approximately 45,000 people in the United States.

The company rebranded from its prior identity to Filana Therapeutics earlier this year, aligning its name with its mechanism focus: modulation of filamin A protein, an oral small-molecule approach targeting CNS disorders associated with filamin A dysregulation or overexpression. The Alzheimer's disease program was fully phased out in Q2 2025, concentrating all development activity on the TSC indication.

Financially, Filana reported Q1 2026 R&D expenses of $4.5 million, down 67% from $13.7 million in Q1 2025, reflecting the exit from the Alzheimer's program. G&A expenses fell 39% year-over-year to $6.6 million, partly because $3.0 million in legal loss contingencies recorded in Q1 2025 did not recur. Net cash used in operations was $8.9 million for the quarter. Cash and equivalents stood at $86.6 million at March 31, 2026, against zero debt, with the company projecting a cash position of $47 to $50 million at June 30, 2026, a drawdown that QA and regulatory leads should read against the timeline uncertainty attached to the Clinical Hold resolution.

The projected cash decline to the $47–$50 million range by mid-year sets a measurable checkpoint against which the company's ability to fund IND-enabling studies will be assessed once the Clinical Hold is lifted.

Source: Filana Therapeutics, Inc. via GlobeNewswire, May 7, 2026.